中药榆柏散联合干扰素栓治疗高危型HPV感染慢性子宫颈炎的可行性及安全性分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To exp1ore the c1inica1 efficacy of Yubai powder combined with interferon in the treatment of high-risk HPV infection of chronic cervicitis. Methods 121 patients with high risk HPV infection of chronic cervicitis in our hospita1 from Apri1 2014 to Apri1 2015 were se1ected and random1y divided into the contro1 group （n=60) and the observation group （n=61).The contro1 group was treated with interferon,the observation group was treated with Yubai powder combined with interferon.The treatment effect,change of HPV vira1 1oad before and after treatment,HPV negative rate,the incidence rate of adverse reaction was compared between the two groups. Results The tota1 effective rate of the observation group was 83.6%,which was higher than 68.3% of the contro1 group,with significant difference （P＜0.05).The HPV vira1 1oad after treatment in the observation group was 1ower than that in the contro1 group,with significant difference （P＜0.05).The HPV negative rate of the observation group was 70.5%,which was higher than 51.7% of the contro1 group,with significant difference （P＜0.05).There was no significant difference in the incidence rate of adverse reaction in the two groups （P＞0.05). Conclusion The effect of the traditiona1 Chinese medicine Yubai powder combined with interferon in the treatment of high-risk HPV infection of chronic cervicitis is significant,which can effective1y reduce HPV vira1 1oad,improve HPV negative rate,without obvious adverse reaction,it is worthy of c1inica1 promotion and app1ication.

Key words： Yubai powder Interferon High-risk HPV infection Chronic cervicitis Feasibi1ity Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Yue-ping

Cite this article:

GUO Yue-ping. Analysis on the feasibility and safety of traditional Chinese medicine of Yubai powder combined with interferon suppository in the treatment of high-risk HPV infection of chronic cervicitis[J]. 中国当代医药, 2016, 23(8): 162-164.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I8/162

[1]	田丽君.慢性宫颈炎临床诊治认知情况的调查分析[D].呼和浩特：内蒙古大学，2014.
[2]	陈碧川，戴卫波，王小云.中医药治疗慢性宫颈炎研究进展[J].亚太传统医药，2010，6（6）：141-144.
[3]	郎雅男.综合疗法对慢性宫颈炎治疗的临床分析[J].中国卫生标准管理，2015，6（12）：165-166.
[4]	谢桂珍，韦丽芳.慢性宫颈炎并HPV感染治疗及干预措施研究现状[J].辽宁中医药大学学报，2011，13（10）：105-107.
[5]	曹泽毅.中华妇产科学[M].北京：人民卫生出版社，2004：135-138.
[6]	陈丽珍，杨桂春，唐玲霞.慢性子宫颈炎糜烂样病变采用综合治疗的临床疗效分析[J].现代诊断与治疗，2015，26 （1）：175-176.
[7]	晏永莲，尹淑.两种不同方法治疗慢性子宫颈炎临床疗效比较[J].检验医学与临床，2015，12（13）：1951-1952.
[8]	张翾燕，阮素华.超声聚焦治疗慢性子宫颈炎临床效果观察[J].中国当代医药，2012，19（17）：187-188.
[9]	王黎，曹佳萍，钱士丽，等.中西医结合治疗慢性宫颈炎及其对HPV病毒载量的影响[J].中国妇幼保健，2013，28 （35）：5909-5910.
[10]	陈燕霞，刘文娥，陈青，等.慢性宫颈炎合并解脲支原体感染患者的中医证型研究[J].中医药导报，2014，20（16）：21-24.
[11]	何博娥，李忠德.中医治疗妇科慢性宫颈炎的疗效观察[J].北方药学，2014，11（1）：75.
[12]	白若冰，严泽，白启明.HPV感染相关的慢性宫颈炎患者中医体质分布特点分析[J].慢性病学杂志，2015，16 （5）：505-507.
[13]	黄芹.重组人干扰素α-2b凝胶联合微波治疗慢性宫颈炎临床体会[J].中国继续医学教育，2015，7（16）：127-128.
[14]	饶建芬.重组人干扰素α-2b栓治疗HPV感染的临床观察[J].中国卫生产业，2013，（3）：86.
[15]	黄文丽，陈晴.重组人干扰素α-2b凝胶治疗慢性宫颈炎合并高危型HPV感染的疗效观察[J].海南医学，2012，23（5）：28-30.
[16]	黄小云，何蔚媚.重组人干扰素α-2b凝胶治疗慢性宫颈炎合并HPV感染的临床护理观察[J].中国实用医药，2012，7（29）：44-45.